ArticleOncoimmunology

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Patrizia Nanni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.